Abstract CT247: A phase 1/2 study of GB1275, a first-in-class CD11b modulator, as monotherapy and with an anti-PD-1 antibody in specified advanced solid tumors or with chemotherapy in metastatic pancreatic cancer (KEYNOTE-A36)
Year: 2020
Type: conference-abstract
Source: Cancer Research
Authors: Andrea Wang-Gillam, Drew W. Rasco, Wungki Park, Eileen O'Reilly, Wells Messersmith, David G. DeNardo, Vineet Gupta, Lei Zhou, Anna Galkin, Debbie Slee, Laura L. Carter, David Nickle, Rebecca Tran, Jack Li, Beatrice Ferguson, Marya F. Chaney, Luisa Salter-Cid, Jakob Dupont, Johanna C. Bendell
Institutions: Washington University in St. Louis, South Texas Accelerated Research Therapeutics, Memorial Sloan Kettering Cancer Center, University of Colorado Denver, Rush University Medical Center, Gossamer Bio (United States), Merck & Co., Inc., Rahway, NJ, USA (United States), Sarah Cannon, Tennessee Oncology
Language: English
Topic: Immune cells in cancer
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W3083234692